NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free CYCN Stock Alerts $3.13 +0.31 (+10.99%) (As of 09:49 AM ET) Add Compare Share Share Today's Range$2.70▼$3.1350-Day Range$2.77▼$3.5052-Week Range$1.75▼$6.75Volume929 shsAverage Volume3,024 shsMarket Capitalization$8.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cyclerion Therapeutics alerts: Email Address Ad StockEarningsThe AI Stock that’s Disrupting Every IndustryMove over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…Here's the Ticker >>> About Cyclerion Therapeutics Stock (NASDAQ:CYCN)Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More CYCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCN Stock News HeadlinesApril 28, 2024 | benzinga.comSage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 21, 2024 | morningstar.comCyclerion Therapeutics Inc Ordinary Shares CYCNMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 5, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023March 6, 2024 | investing.comCyclerion Therapeutics Inc (CYCN)February 29, 2024 | uk.finance.yahoo.comCyclerion Therapeutics, Inc. (CYCN)February 23, 2024 | benzinga.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesDecember 4, 2023 | msn.comCyclerion Therapeutics appoints Graul as PresidentMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.November 30, 2023 | finance.yahoo.comCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNovember 28, 2023 | finance.yahoo.comCyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesJuly 31, 2023 | finance.yahoo.comTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsJune 30, 2023 | ca.finance.yahoo.comCYCN - Cyclerion Therapeutics, Inc.June 2, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 1, 2023 | msn.comCyclerion Therapeutics in compliance with Nasdaq minimum bid price ruleMay 16, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock SplitMay 15, 2023 | msn.comCyclerion announces 1 for 20 reverse stock splitMay 12, 2023 | finance.yahoo.comCyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New InvestorsMay 12, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 12, 2023 | msn.comCyclerion Therapeutics down 6% on spin off agreementMay 11, 2023 | finance.yahoo.comCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comCyclerion Announces Definitive Agreement for Zagociguat and CY3018April 3, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementMarch 27, 2023 | marketwatch.comCyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCNMarch 23, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsMarch 22, 2023 | finance.yahoo.comCyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNovember 23, 2022 | msn.comWhy American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From YesterdaySee More Headlines Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYCN CUSIPN/A CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,260,000.00 Net MarginsN/A Pretax Margin-742.76% Return on Equity-111.79% Return on Assets-74.10% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual Sales$1.62 million Price / Sales4.75 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.61Miscellaneous Outstanding Shares2,710,000Free Float2,355,000Market Cap$7.70 million OptionableNo Data Beta1.84 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Regina Graul Ph.D.PresidentMs. Rhonda M. Chicko (Age 57)Chief Financial Officer Dr. Todd Milne Ph.D.Senior Vice President of External InnovationMs. Jessica RennekampAssociate Director of Corporate CommunicationsKey CompetitorsBionomicsNASDAQ:BNOXObsEvaNASDAQ:OBSVChemomab TherapeuticsNASDAQ:CMMBAddex TherapeuticsNASDAQ:ADXNTenax TherapeuticsNASDAQ:TENXView All CompetitorsInsiders & InstitutionsTyndall Capital Partners L PBought 16,717 shares on 2/14/2024Ownership: 6.711%Terrance McguireSold 8 sharesTotal: $27.20 ($3.40/share)View All Insider TransactionsView All Institutional Transactions CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed in 2024? Cyclerion Therapeutics' stock was trading at $3.35 at the start of the year. Since then, CYCN stock has decreased by 15.2% and is now trading at $2.84. View the best growth stocks for 2024 here. Are investors shorting Cyclerion Therapeutics? Cyclerion Therapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 20,200 shares, a decrease of 8.6% from the March 31st total of 22,100 shares. Based on an average daily trading volume, of 2,900 shares, the short-interest ratio is presently 7.0 days. Currently, 1.0% of the company's shares are sold short. View Cyclerion Therapeutics' Short Interest. When is Cyclerion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CYCN earnings forecast. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($5.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.00) by $1.80. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $3 million. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics's stock reverse split on the morning of Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX). Who are Cyclerion Therapeutics' major shareholders? Cyclerion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Peter M Hecht, Peter M Hecht, Slate Path Capital Lp and Terrance Mcguire. View institutional ownership trends. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCN) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
